This site is intended for health professionals only

Published on 10 May 2010

Share this story:
Twitter
LinkedIn

Pramipexole shows Parkinson’s hope

teaser

Dopamine agonist pramipexole improves motor skills and alleviates depression in people with Parkinson’s disease (PD), a study has found.

The investigation, published in the Lancet Neurology, used a randomised trial to measure the safety and efficacy of the drug in patients with mild-to-moderate PD.

Lead researcher Paolo Barone, from the University of Naples, Italy, found that the treatment significantly improved depressive symptoms when compared with a placebo.

The authors said: “These results suggest that specific stimulation of dopaminergic pathways as provided by pramipexole should be considered in the management of patients with PD and clinically-significant depressive symptoms.”

Depression is a common symptom of Parkinson’s, hitting around 35% of sufferers.

The study is the first to show the direct benefits of a dopamine agonist for people with PD.

Copyright Press Association 2010
The Lancet



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn